ATXS

ATXS

USD

Astria Therapeutics Inc. Common Stock

$12.250+0.120 (0.989%)

वास्तविक समय मूल्य

Healthcare
जैव प्रौद्योगिकी
संयुक्त राज्य अमेरिका

मूल्य चार्ट

Loading Chart...

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$12.130

उच्च

$12.390

कम

$12.110

मात्रा

1.43M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

691.3M

उद्योग

जैव प्रौद्योगिकी

देश

United States

ट्रेडिंग आँकड़े

औसत मात्रा

1.58M

एक्सचेंज

NGM

मुद्रा

USD

52-सप्ताह रेंज

कम $3.555वर्तमान $12.250उच्च $12.715

संबंधित समाचार

BusinessWire

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the

और देखें
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
PR Newswire

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

और देखें
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders
Analyst Upgrades

JMP Securities Downgrades Astria Therapeutics to Market Perform

JMP Securities analyst Jonathan Wolleben downgrades Astria Therapeutics from Market Outperform to Market Perform.

और देखें
JMP Securities Downgrades Astria Therapeutics to Market Perform
PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

और देखें
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)
Analyst Upgrades

Jefferies Downgrades Astria Therapeutics to Hold, Lowers Price Target to $13

Jefferies analyst Eun Yang downgrades Astria Therapeutics from Buy to Hold and lowers the price target from $30 to $13.

और देखें
Jefferies Downgrades Astria Therapeutics to Hold, Lowers Price Target to $13
PR Newswire

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS, PCH, RYN on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PR Newswire

Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

The Ademi Firm is investigating Astria (NASDAQ: ATXS) for possible breaches of fiduciary duty and other violations of law in its transaction with...

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।